The sentinel node is the first lymph node to receive drainage from a tumor. Examining it can provide evidence about whether malignant cells have moved from the primary tumor into regional lymphatic tissue. This makes sentinel-node selection useful for connecting local tumor behavior with lymphatic spread and for supporting cancer staging.
Microscopic examination determines whether the sampled tissue contains malignant cells. Those findings help characterize the extent of disease beyond the primary tumor, contributing to staging and prognosis. In turn, clinicians can use the pathology result to support treatment planning when assessing whether regional lymphatic involvement is present.
The collected tissue can support molecular analyses of tumor biology, extending evaluation beyond the microscopic presence or absence of malignant cells. Researchers can use these analyses to investigate characteristics of the tumor and its therapeutic response. This creates a link between diagnostic sampling and studies of how cancer behaves or responds to treatment.
Sampling may involve an imaging-guided needle or removal of a selected lymph node. Imaging can help guide the needle toward the intended tissue, while selected-node removal provides a specimen for pathological examination. The approach therefore determines how the relevant axillary tissue is obtained before microscopic and, when appropriate, molecular assessment.
It is relevant when investigators or clinicians need information about possible spread through regional lymphatic tissue. The resulting findings can contribute to staging, prognosis, and treatment planning. In research, the same specimens may also provide material for examining tumor biology and therapeutic response, making the procedure useful for both disease assessment and scientific investigation.
Results provide evidence about whether malignant cells are present in lymphatic tissue associated with the primary tumor. That evidence helps indicate the extent of disease, which contributes to staging and prognosis. Because treatment planning depends partly on disease extent, the pathology findings can help guide decisions about the broader cancer management approach.